<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132306">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379521</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001OHK02</org_study_id>
    <nct_id>NCT01379521</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC</brief_title>
  <acronym>TRACER</acronym>
  <official_title>A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor®) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the role of everolimus in combination with local Transcatheter
      Arterial Chemoembolization (TACE) procedure in patients suffering from localized
      unresectable Hepatocellular Carcinoma (HCC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the anti-tumor effect, measured by Time to Progression (TTP), of everolimus (RAD001, Afinitor®) systemic treatment combined with local TACE procedure as compared to local TACE alone, based on the modified RECIST criteria</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the benefit of the combination strategy as measured by the overall response rate (ORR) and disease control rate (DCR), based on the modified RECIST criteria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the differences between the two treatment groups in TTP, ORR and DCR rate, based on the original RECIST criteria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the benefit of the combination strategy as measured by overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the difference between the two treatment groups in incidences of cumulative new nodular recurrence, portal vein invasion and extrahepatic metastases</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) as determined by CTCAE version 4.02, serious adverse events (SAEs), discontinuation rate and tolerability of the combination strategy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>everolimus + transcatheter arterial chemoembolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus placebo + transcatheter arterial chemoembolization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <arm_group_label>everolimus + transcatheter arterial chemoembolization</arm_group_label>
    <other_name>RAD001</other_name>
    <other_name>Afinitor®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus placebo</intervention_name>
    <arm_group_label>everolimus placebo + transcatheter arterial chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed hepatocellular carcinoma limited to liver and not suitable for
             resection, liver transplant, or radiofrequency ablation.

          -  Intermediate stage (stage B) (according to recognized guidelines) and suitable for
             TACE therapy

          -  At least one nodule between &gt; 2cm and ≤ 15cm in diameter with no vascular invasion or
             abdominal lymph node or distant metastases.

          -  Must have 1 tumor which can be measured in 1 dimension according to specified
             criteria (RECIST and mRECIST) and has not previously been treated with any type of
             therapy.

          -  ECOG performance status &lt; 2cm

          -  Cirrhotic status of Child-Pugh class A or early B

          -  HBV-DNA or HBsAg positive at screen or baseline: preventative treatment with
             anti-viral started 1-2 weeks prior to receiving study drug

        Exclusion Criteria:

          -  Any local and/or investigational drugs within 28 days prior to randomization

          -  Active bleeding during the last 28 days prior to screening including variceal
             bleeding

          -  Prior therapy with mTOR inhibitors

          -  Tumor burden of &gt; 60% liver involvement

          -  Prior systemic or local therapy including TACE except for the first TACE at Day 0),
             surgery or liver transplantation

          -  Failed first TACE at Day 0, Cycle 1 for any reason

          -  Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is
             not mandatory)

          -  Alcohol intake of 80 grams per day

          -  Undergone major surgery ≤ 3 weeks prior to starting study drug or who have not
             recovered from surgery

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Kou</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 13, 2016</lastchanged_date>
  <firstreceived_date>June 1, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Localised</keyword>
  <keyword>unresectable</keyword>
  <keyword>chemoembolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
